Division of Cardiology Weill Cornell Medical College New York Presbyterian Hospital New York NY.
J Am Heart Assoc. 2020 Dec;9(23):e017326. doi: 10.1161/JAHA.120.017326. Epub 2020 Nov 23.
Background Cardiogenic shock (CS) is a complex syndrome associated with high morbidity and mortality. In recent years, many US hospitals have formed multidisciplinary shock teams capable of rapid diagnosis and triage. Because of preexisting collaborative systems of care, hospitals with left ventricular assist device (LVAD) programs may also represent "centers of excellence" for CS care. However, the outcomes of patients with CS at LVAD centers have not been previously evaluated. Methods and Results Patients with CS were identified in the 2012 to 2014 National Inpatient Sample. Clinical characteristics, revascularization rates, and use of mechanical circulatory support were analyzed in LVAD versus non-LVAD centers. The association between hospital type and in-hospital mortality was examined using multivariable logistic regression models. Of 272 075 hospitalizations, 26.0% were in LVAD centers. CS attributable to causes other than acute myocardial infarction represented most cases. In-hospital mortality was lower in LVAD centers (38.9% versus 43.3%; <0.001). In multivariable analysis, the odds of mortality remained significantly lower for hospitalizations in LVAD centers (odds ratio, 0.89; <0.001). In patients with CS secondary to acute myocardial infarction, revascularization rates were similar between LVAD and non-LVAD centers. The use of intra-aortic balloon pump (18.7% versus 18.8%) and Impella/TandemHeart (2.6% versus 1.9%) was similar between hospital types, whereas extracorporeal membrane oxygenation was used more frequently in LVAD centers (4.3% versus 0.2%; <0.001). Conclusions Risk-adjusted mortality was lower in patients with CS who were hospitalized at LVAD centers. These centers likely represent specialized, shock team capable institutions across the country that may be best suited to manage patients with CS.
背景 心原性休克(CS)是一种与高发病率和死亡率相关的复杂综合征。近年来,许多美国医院已经组建了多学科休克团队,能够快速进行诊断和分诊。由于预先存在的协作护理系统,配备左心室辅助装置(LVAD)的医院也可能代表 CS 治疗的“卓越中心”。然而,之前尚未评估 LVAD 中心 CS 患者的结局。
方法和结果 在 2012 年至 2014 年全国住院患者样本中确定 CS 患者。分析 LVAD 与非 LVAD 中心的临床特征、血运重建率和机械循环支持的使用情况。使用多变量逻辑回归模型检查医院类型与院内死亡率之间的关联。在 272075 例住院患者中,26.0%在 LVAD 中心。除急性心肌梗死以外的原因引起的 CS 占大多数病例。LVAD 中心的院内死亡率较低(38.9%比 43.3%;<0.001)。多变量分析表明,LVAD 中心住院的死亡风险显著降低(比值比,0.89;<0.001)。在 CS 继发于急性心肌梗死的患者中,LVAD 和非 LVAD 中心的血运重建率相似。LVAD 和非 LVAD 中心的主动脉内球囊泵(18.7%比 18.8%)和 Impella/TandemHeart(2.6%比 1.9%)的使用相似,而 LVAD 中心更常使用体外膜肺氧合(4.3%比 0.2%;<0.001)。
结论 在 LVAD 中心住院的 CS 患者的风险调整死亡率较低。这些中心可能代表全国范围内专门的、配备休克团队的机构,可能最适合治疗 CS 患者。